美沙拉嗪联合酪酸梭菌肠球菌三联活菌片治疗活动期溃疡性结肠炎的价值研究

Clinical value research of mesalazine combined with clostridium butyricum enterococcus triple viable tablets in treatment of active ulcerative colitis

目的探究美沙拉嗪联合酪酸梭菌肠球菌三联活菌片治疗活动期溃疡性结肠炎患者的临床应用价值。方法随机选取2013年1月~2016年1月我院收治的活动期溃疡性结肠炎患者60例,根据治疗方法的不同分为对照组与实验组。对照组30例,给予美沙拉嗪治疗。实验组30例,给予美沙拉嗪与酪酸梭菌肠球菌三联活菌片联合治疗。比较两组患者临床疗效、治疗前后IL-4、hs-CRP、IL-8水平及不良反应发生率及复发率。结果实验组治疗有效率(93.33%)明显高于对照组(73.33%),差异具有统计学意义(P<0.05)。治疗前,两组患者IL-4、hs-CRP、IL-8水平比较差异均无统计学意义(P>0.05),治疗后,两组hs-CRP、IL-8水平均降低,且实验组低于对照组,IL-4水平均升高,且实验组高于对照组,差异均具有统计学意义(P<0.05)。实验组不良反应发生率(6.67%)明显低于对照组(26.67%),复发率(3.33%)低于对照组(20.00%),差异均具有统计学意义(P<0.05)。结论美沙拉嗪与酪酸梭菌肠球菌三联活菌片联合治疗可在降低活动期溃疡性结肠炎患者不良反应发生率与复发率的同时,显著缓解患者临床症状,减轻炎症反应,提高临床疗效,是一种安全、有效的治疗方式。

Objective To study clinical value of mesalazine combined with clostridium butyricum enterococcus triple viable tablets in treatment of active ulcerative colitis. Methods 60 cases of patients with active ulcerative colitis cured in our hospital from January 2013 to January 2016 were randomly selected. They were divided into control group and experimental group according to different treatment method. 30 cases were divided into control group, and they were treated with mesalazine. 30 cases were divided into exprimental group, and they were treated with mesalazine combined with clostridium butyricum enterococcus triple viable tablets. Clinical efficacy, IL-4, hs-CRP, IL-8 levels and incidence of adverse reactions and recurrence rate before and after treatment of the two groups were compared. Results The effective rate of the experimental group （93.33%） was significantly higher than that of the control group （73.33%）, and the difference was statistically significant （P 〈 0.05）. Before treatment, the differences of IL-4, hs-CRP and IL-8 between the 2 groups were not statistically significant （P 〉 0.05）. After treatment, hs- CRP, IL-8 water of the two groups were decreased, and the experimental group was lower than the control group, IL-4 levels of the two groups were elevated, and the experimental group was higher than the control group, the difference was statistically significant （P 〈 0.05）. The incidence of adverse reactions in the experimental group （6.67%） was significantly lower than that in the control group （26.67%）, and the recurrence rate （3.33%） was lower than that in the control group （20.00%）, and the difference was statistically significant （P 〈 0.05）. Conclusion The combined treatment of mesalazine and clostridium hutyricum enterococcus triple viable tablets and reduce the incidence of adverse reactions and recurrence rate in patients with active ulcerative colitis. On the same time, it can significantly reduce the clinical symptoms, reduce inflammation, and improve clinical efficacy. It is a safe and effective treatment.